Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)Zurina Cinza-Estévez, Y. RodriguezGuevara, Nelvis Lázara Figueroa-Baile et al.|EClinicalMedicine|2023Cited by 6